Feasibility of Computed Tomography in a Multicenter COPD Trial: A Study of the Effect of AZD9668 on Structural Airway Changes
Conclusions This study confirmed the feasibility of using CT to assess structural airway changes in COPD. However, there was no evidence of improvements in CT structural measures following 12 weeks’ treatment with AZD9668 60 mg BID. Funding AstraZeneca. (Source: Advances in Therapy)
Source: Advances in Therapy - June 5, 2015 Category: Drugs & Pharmacology Source Type: research

The Potential Role of an Extended-Release, Abuse-Deterrent Oxycodone/Acetaminophen Fixed-Dose Combination Product for the Treatment of Acute Pain
Abstract Acute pain, prevalent as part of postoperative and traumatic pain, is often sub-optimally or inadequately treated. Fixed-dose combination analgesic products that combine a reduced amount of opioid with a nonopioid analgesic such as acetaminophen (paracetamol) in a single tablet offer potential pharmacodynamic and/or pharmacokinetic benefits, and may also result in an opioid-sparing effect. A new analgesic product (XARTEMIS™ XR, Mallinckrodt Brand Pharmaceuticals, Dublin, Ireland) combines oxycodone (7.5 mg) with acetaminophen (325 mg) in an immediate-release/extended-release (ER) formulati...
Source: Advances in Therapy - May 31, 2015 Category: Drugs & Pharmacology Source Type: research

Cost–Utility of First-Line Actinic Keratosis Treatments in Finland
Conclusion IngMebs were cost-effective AK treatments in Finland. Funding LEO Pharma. (Source: Advances in Therapy)
Source: Advances in Therapy - May 26, 2015 Category: Drugs & Pharmacology Source Type: research

Cumulative Review of Thrombotic Microangiopathy, Thrombotic Thrombocytopenic Purpura, and Hemolytic Uremic Syndrome Reports with Subcutaneous Interferon β-1a
Conclusion No new signal relating specifically to increased frequency of TMA/TTP-HUS with HSA-free subcutaneous interferon β-1a was detected and no additional risk mitigation measures are required regarding the different formulations. The benefit–risk balance of subcutaneous interferon β-1a remains positive, and routine pharmacovigilance monitoring is appropriate. Funding Ares Trading SA, Aubonne, Switzerland, a subsidiary of Merck Serono SA. (Source: Advances in Therapy)
Source: Advances in Therapy - May 20, 2015 Category: Drugs & Pharmacology Source Type: research

Absence of Drug–Drug Interactions Between Luseogliflozin, a Sodium–Glucose Co-transporter-2 Inhibitor, and Various Oral Antidiabetic Drugs in Healthy Japanese Males
Conclusion No clinically meaningful interactions were observed between luseogliflozin and six commonly used OADs in Japan, although there were some changes in the pharmacokinetics of pioglitazone co-administered with luseogliflozin and for luseogliflozin co-administered with miglitol or pioglitazone. Funding Taisho Pharmaceutical Co., Ltd. (Source: Advances in Therapy)
Source: Advances in Therapy - May 15, 2015 Category: Drugs & Pharmacology Source Type: research

Evaluation of the Safety Profile of Zolafren ® , a Generic Olanzapine Formulation, in Patients with Bipolar Disorder: A Post-Authorization Safety Study
Conclusion The results of this PASS support the safety of Zolafren use and indicate a high tolerance in patients treated for BD. Funding Adamed Sp. z o.o., Czosnów, Poland. (Source: Advances in Therapy)
Source: Advances in Therapy - May 15, 2015 Category: Drugs & Pharmacology Source Type: research

Real-World Determinants of Adjunctive Antipsychotic Prescribing for Patients with Major Depressive Disorder and Inadequate Response to Antidepressants: A Case Review Study
Conclusion This real-world study suggested that the decision to prescribe an adjunctive antipsychotic for patients with MDD and inadequate response to ADT is influenced by a broad spectrum of factors, predominantly related to severity of illness, functional impairment, and symptom profile. Funding Otsuka Pharmaceutical Development & Commercialization, Inc. (Princeton, USA) and H. Lundbeck A/S (Valby, Denmark). (Source: Advances in Therapy)
Source: Advances in Therapy - May 13, 2015 Category: Drugs & Pharmacology Source Type: research

Minimizing Hypoglycemia and Weight Gain with Intensive Glucose Control: Potential Benefits of a New Combination Therapy (IDegLira)
This article discusses the rationale behind combining these two drug classes and reviews the available clinical evidence for the efficacy and safety of IDegLira. (Source: Advances in Therapy)
Source: Advances in Therapy - May 12, 2015 Category: Drugs & Pharmacology Source Type: research

Release of 5-Aminosalicylic Acid (5-ASA) from Mesalamine Formulations at Various pH Levels
Conclusion 5-Aminosalicylic acid release profiles were variable among various commercially available formulations. Funding Shire Development LLC. (Source: Advances in Therapy)
Source: Advances in Therapy - May 8, 2015 Category: Drugs & Pharmacology Source Type: research

Patient Reported Burden of Asthma on Resource Use and Productivity Across 11 Countries in Europe
Conclusion This study quantified utilization of healthcare resources in asthma (number of visits of HCPs, hospitalization, and accident and emergency visits) as well as absenteeism and showed that differences exist across countries. The differences in primary care and specialist use suggest a possible difference in healthcare delivery across countries. Funding Mundipharma International Limited, Cambridge, UK. (Source: Advances in Therapy)
Source: Advances in Therapy - April 25, 2015 Category: Drugs & Pharmacology Source Type: research

A 1-Year Randomized Study of the Clinical and Confocal Effects of Tafluprost and Latanoprost in Newly Diagnosed Glaucoma Patients
Abstract Introduction The aim of the present study was to compare the confocal and clinical features of newly diagnosed glaucoma patients receiving unpreserved prostaglandins (tafluprost) versus preserved prostaglandins (latanoprost). Materials and Methods 40 patients were randomized to tafluprost 0.0015% (20 patients; 32 eyes) or latanoprost 0.005% + benzalkonium chloride 0.02% (20 patients; 35 eyes) once daily for 1 year. Inclusion criteria were new glaucoma diagnosis, and no ocular treatments for 6 months before the study. Patients...
Source: Advances in Therapy - April 19, 2015 Category: Drugs & Pharmacology Source Type: research

Erratum to: Effect of Rivaroxaban Versus Warfarin on Health Care Costs Among Nonvalvular Atrial Fibrillation Patients: Observations from Rivaroxaban Users and Matched Warfarin Users
(Source: Advances in Therapy)
Source: Advances in Therapy - April 17, 2015 Category: Drugs & Pharmacology Source Type: research

Does Defibrotide Induce a Delay to Polymorphonuclear Neutrophil Engraftment After Hematopoietic Stem Cell Transplantation? Observation in a Pediatric Population
Conclusion Our study supports the hypothesis that prophylaxis with DFT for VOD leads to a delay to the engraftment of PMN in pediatric patients that underwent HSCT. (Source: Advances in Therapy)
Source: Advances in Therapy - April 16, 2015 Category: Drugs & Pharmacology Source Type: research

Pharmacokinetics, Pharmacodynamics, and Safety of Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus: A Randomized, Single-blind, Placebo-controlled Trial
Conclusion Once-daily administration of luseogliflozin for 7 days increased 24-h UGE in a dose-dependent manner, reduced plasma glucose concentrations, and was well tolerated in Japanese patients with T2DM. The pharmacokinetic and pharmacodynamic profile of luseogliflozin observed in this study supports its once-daily dosing regimen. Funding Taisho Pharmaceutical Co., Ltd. (Source: Advances in Therapy)
Source: Advances in Therapy - April 9, 2015 Category: Drugs & Pharmacology Source Type: research

Asthma Control: The Right Inhaler for the Right Patient
Abstract Inhaled therapy is the cornerstone of asthma management in that it optimizes the delivery of the medication to the site of action. The effectiveness of inhaled therapy is affected by the correct choice of the device and proper inhalation technique. In fact, this influences the drug delivery and distribution along the bronchial tree, including the most peripheral airways. In this context, accumulating evidence supports the contribution of small airways in asthma, and these have become an important target of treatment. In reality, the “ideal inhaler” does not exist, and not all inhalers are the ...
Source: Advances in Therapy - April 7, 2015 Category: Drugs & Pharmacology Source Type: research

Efficacy and Safety of Empagliflozin Monotherapy for 52 Weeks in Japanese Patients with Type 2 Diabetes: A Randomized, Double-Blind, Parallel-Group Study
Conclusion Empagliflozin monotherapy for 52 weeks led to sustained reductions in HbA1c, FPG, weight and BP and was well tolerated in Japanese patients with T2DM. Funding Boehringer Ingelheim and Eli Lilly and Company. (Source: Advances in Therapy)
Source: Advances in Therapy - April 7, 2015 Category: Drugs & Pharmacology Source Type: research

Erratum to: Management of Bone Disease in Gaucher Disease Type 1: Clinical Practice
(Source: Advances in Therapy)
Source: Advances in Therapy - April 3, 2015 Category: Drugs & Pharmacology Source Type: research

A Biopsychosocial Model for the Management of Patients With Sickle-Cell Disease Transitioning to Adult Medical Care
We describe the challenges and issues encountered by these patients, and we propose a biopsychosocial multidisciplinary approach to the management of the identified issues. Examples of this approach, such as transition-focused integrated care models and quality improvement collaboratives, with the potential to improve health outcomes in adulthood are also described. (Source: Advances in Therapy)
Source: Advances in Therapy - April 2, 2015 Category: Drugs & Pharmacology Source Type: research

Impact of Medication Adherence and Persistence on Clinical and Economic Outcomes in Patients with Type 2 Diabetes Treated with Liraglutide: A Retrospective Cohort Study
This study examines how adherence and persistence to once-daily liraglutide impact glycemic control and economic outcomes in a real-world population of adult type 2 diabetes (T2D) patients. Methods A retrospective cohort study using administrative claims data from July 2009 through September 2013. Patients aged ≥18 years with T2D treated with liraglutide were identified (index date = first liraglutide prescription). Adherence was based on the proportion of days covered (PDC); with PDC ≥0.80 classified as adherent. Non-persistent patients were those with a gap in ...
Source: Advances in Therapy - April 2, 2015 Category: Drugs & Pharmacology Source Type: research

Efficacy and Safety of Linagliptin Co-Administered with Low-Dose Metformin Once Daily Versus High-Dose Metformin Twice Daily in Treatment-Naïve Patients with Type 2 Diabetes: a Double-Blind Randomized Trial
Abstract Introduction The aim of this study was to investigate the efficacy and safety of linagliptin + low-dose (LD) metformin once daily versus high-dose (HD) metformin twice daily in treatment-naïve patients with type 2 diabetes. Methods Patients (n = 689) were randomized (1:1) to double-blind treatment with linagliptin 5 mg + LD metformin (1000 mg) or HD metformin (2000 mg) for 14 weeks. Metformin was initiated at 500 mg/day and up-titrated within 2 weeks; the dose then remained unchang...
Source: Advances in Therapy - March 25, 2015 Category: Drugs & Pharmacology Source Type: research

Effect of Rivaroxaban Versus Warfarin on Health Care Costs Among Nonvalvular Atrial Fibrillation Patients: Observations from Rivaroxaban Users and Matched Warfarin Users
This study aimed to assess, among patients with NVAF, the effect of rivaroxaban versus warfarin on health care costs in a cohort of rivaroxaban users and matched warfarin users. Methods Health care claims from the Humana database from 5/2011 to 12/2012 were analyzed. Adult patients newly initiated on rivaroxaban or warfarin with ≥2 atrial fibrillation (AF) diagnoses (The International Classification of Diseases, Ninth Revision, Clinical Modification: 427.31) and without valvular AF were identified. Based on propensity score methods, warfarin patients were matched 1:1 to rivar...
Source: Advances in Therapy - March 18, 2015 Category: Drugs & Pharmacology Source Type: research

Echinacea Reduces the Risk of Recurrent Respiratory Tract Infections and Complications: A Meta-Analysis of Randomized Controlled Trials
Abstract Introduction Respiratory tract infections are common, and these infections occur frequently in children, susceptible adults, and older persons. The risk for recurrences and complications relates not only to the presence of viruses but also to immune function. Therefore, modulation of the immune system and antiviral interventions such as echinacea might reduce the risk of recurrences and possibly the development of complications. Methods MEDLINE, EMBASE, CAplus, BIOSIS, CABA, AGRICOLA, TOXCENTER, SCISEARCH, NAHL, and NAPRALERT were searched for c...
Source: Advances in Therapy - March 18, 2015 Category: Drugs & Pharmacology Source Type: research

Nomenclature and Traceability Debate for Biosimilars: Small-Molecule Surrogates Lend Support for Distinguishable Nonproprietary Names
Conclusion Use of the same nonproprietary name for generic and branded products may contribute to poor traceability of AEs reported in the FAERS database due to the significant misattribution of AEs to branded products (when those AEs were in fact associated with patient use of generic products). To ensure accurate and robust safety surveillance and traceability for biosimilar products in the United States, improved product identification mechanisms, such as related but distinguishable nonproprietary names for biosimilars and reference biologics, should be considered. (Source: Advances in Therapy)
Source: Advances in Therapy - March 13, 2015 Category: Drugs & Pharmacology Source Type: research

Cost-Effectiveness Analysis of Mometasone Furoate Versus Beclomethasone Dipropionate for the Treatment of Pediatric Allergic Rhinitis in Colombia
Conclusion The present analysis shows that in Colombia, compared with BDNS, therapy with MFNS for treating pediatric patients with AR is a dominant strategy because it showed a greater improvement in a TIX reflecting both efficacy and safety, at lower total treatment costs. (Source: Advances in Therapy)
Source: Advances in Therapy - March 10, 2015 Category: Drugs & Pharmacology Source Type: research

Clinical Pharmacokinetics of the Anti-Interleukin-20 Monoclonal Antibody NNC0109-0012 in Healthy Volunteers and Patients with Psoriasis or Rheumatoid Arthritis
Conclusion The PK profile of NNC0109-0012 is similar to other monoclonal antibodies directed against soluble targets. (Source: Advances in Therapy)
Source: Advances in Therapy - March 7, 2015 Category: Drugs & Pharmacology Source Type: research

Cost-Effectiveness of the 21-Gene Breast Cancer Assay in Mexico
Conclusion In early-stage breast cancer patients in Mexico, guiding decision making on adjuvant therapy using the 21-gene assay was projected to improve life expectancy in comparison with the current standard of care, with an ICER of MXN 25,244 (USD 1914) per life-year gained, which is within the range generally considered cost-effective. (Source: Advances in Therapy)
Source: Advances in Therapy - March 5, 2015 Category: Drugs & Pharmacology Source Type: research

Measles in Morocco: Epidemiological Profile and Impact of Vaccination Strategy
Conclusion The vaccination plan and the surveillance system executed in Morocco within the framework of the regional project implemented by the World Health Organization (WHO) to eliminate measles has given remarkable results regarding the reduction of measles cases and mortality due to this disease. According to the data from MoH and WHO, the number of reported and confirmed measles cases decreased drastically during 2014. However, these efforts are still unsatisfactory compared to the prospective of eliminating the disease by 2015. (Source: Advances in Therapy)
Source: Advances in Therapy - March 3, 2015 Category: Drugs & Pharmacology Source Type: research

The Cost of Thromboembolic Events in Hospitalized Patients with Breast or Prostate Cancer in France
Conclusion The burden of VTE in cancer patients is important; costs should be reduced by decreasing the occurrence of thrombotic recurrences. In this respect, better prevention and follow-up measures may reduce recurrence and VTE costs. (Source: Advances in Therapy)
Source: Advances in Therapy - February 26, 2015 Category: Drugs & Pharmacology Source Type: research

Erratum to: The Fixed-Dose Combination of Olmesartan/Amlodipine Was Superior in Central Aortic Blood Pressure Reduction Compared with Perindopril/Amlodipine: A Randomized, Double-Blind Trial in Patients with Hypertension
(Source: Advances in Therapy)
Source: Advances in Therapy - February 25, 2015 Category: Drugs & Pharmacology Source Type: research

A Randomized, Crossover Study to Investigate the Pharmacokinetics and Safety of Inhaled Fluticasone Furoate and Umeclidinium, Administered Separately and in Combination via Dry Powder Inhaler in Healthy Adult Volunteers
Conclusion Fluticasone furoate and umeclidinium co-administration was well tolerated and was not associated with meaningful changes in systemic or urinary PK versus the monotherapies. Funding GlaxoSmithKline. (Source: Advances in Therapy)
Source: Advances in Therapy - February 21, 2015 Category: Drugs & Pharmacology Source Type: research

Addition of Ivabradine to β-Blocker Improves Exercise Capacity in Systolic Heart Failure Patients in a Prospective, Open-Label Study
Abstract Introduction Difficulties initiating and uptitrating β-blockers due to tolerability can complicate management of heart failure. Among other actions, β-blockers reduce heart rate, which is an important cardiovascular risk factor in heart failure. A new therapeutic strategy is ivabradine, which reduces resting heart rate and is associated with improved outcomes. Methods A 5-month, prospective, open-label, nonrandomized single-center study was performed in 69 patients. All patients had chronic heart failure with left ventricular systolic ...
Source: Advances in Therapy - February 21, 2015 Category: Drugs & Pharmacology Source Type: research

IPF Care: A Support Program for Patients with Idiopathic Pulmonary Fibrosis Treated with Pirfenidone in Europe
Abstract Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, and irreversible fibrotic lung disease that requires long-term treatment. Given the importance of adherence to treatment and management of adverse events (AEs), patients with IPF need long-term, high-quality support in living with their condition, and adhering to therapy so they can derive maximum benefit. The IPF Care Patient Support Program (IPF Care) provides support, education, and empowerment to patients receiving pirfenidone for the treatment of IPF in Europe, through the provision of frequent, patient-managed discussions with specialist...
Source: Advances in Therapy - February 18, 2015 Category: Drugs & Pharmacology Source Type: research

Ivabradine in Combination with Beta-Blockers in Patients with Chronic Stable Angina After Percutaneous Coronary Intervention
We describe a post hoc analysis in the ADDITIONS database to investigate effectiveness and tolerability of ivabradine in combination with beta-blocker in patients with angina who have had a percutaneous coronary intervention (PCI). Methods ADDITIONS was a non-interventional, multicenter prospective study including 2,330 patients with stable angina. In addition to beta-blocker, patients were treated with ivabradine in approved dosages for 4 months. We divided the population according to whether they had previously had a PCI or not, and explored the effect of ivabradine on heart r...
Source: Advances in Therapy - February 17, 2015 Category: Drugs & Pharmacology Source Type: research

A Follow-up Study to Monitor Adult Height Among Spanish Children with Growth Hormone Deficiency Who Received Biosimilar Human Recombinant Growth Hormone (Omnitrope ® ) During a Phase III Clinical Trial
Conclusion This cohort of Spanish patients with GHD showed a positive response to rhGH treatment, achieving adult height within the local normal ranges. In addition, rhGH treatment was well tolerated, with no new or additional safety concerns. (Source: Advances in Therapy)
Source: Advances in Therapy - February 11, 2015 Category: Drugs & Pharmacology Source Type: research

Current Adjuvant Therapeutic Approaches for Pancreatic Cancer
Abstract Pancreatic cancer continues to be the fourth leading cause of death despite advancements in surgical and adjuvant therapeutic approaches. In the present review, the current cytotoxic therapeutic approaches and advanced targeted therapies are objectively discussed with consideration to the current literature. (Source: Advances in Therapy)
Source: Advances in Therapy - January 1, 2015 Category: Drugs & Pharmacology Source Type: research

Early Direct and Indirect Impact of Quadrivalent HPV (4HPV) Vaccine on Genital Warts: a Systematic Review
Abstract Introduction Since 2007, many countries have implemented national human papillomavirus (HPV) vaccination programs with the quadrivalent HPV (4HPV) vaccine that has been shown to be efficacious in clinical trials involving 25,000 subjects. Two vaccine serotypes, HPV16 and 18, are responsible for cervical cancer and other HPV-related cancers, but the impact of the 4HPV vaccine on these cancers cannot be seen immediately as there is a considerable lag between infection with HPV and cancer development. The other two serotypes, HPV6 and 11, are responsible for genital warts (GWs), which...
Source: Advances in Therapy - January 1, 2015 Category: Drugs & Pharmacology Source Type: research

Cost-Effectiveness of Point-of-Care C-Reactive Protein Tests for Respiratory Tract Infection in Primary Care in England
Conclusion The additional cost per patient of the CRP test is outweighed by the associated cost savings and QALY increment associated with a reduction in infections in the long term. (Source: Advances in Therapy)
Source: Advances in Therapy - January 1, 2015 Category: Drugs & Pharmacology Source Type: research

A Review of Uric Acid, Crystal Deposition Disease, and Gout
Abstract There has been increased interest in gout in both academic and clinical practice settings. Several reasons may explain this. The prevalence of both hyperuricemia and gout has risen in the last decades in developed countries and therefore the burden of gout has increased. The association of hyperuricemia and gout with cardiovascular outcomes and the opportunity of further benefits of intervention on hyperuricemia have been recently highlighted in the literature. Imaging techniques have proven to be useful for detection of urate deposition, even prior to the first clinical symptoms, enabling the evaluation...
Source: Advances in Therapy - January 1, 2015 Category: Drugs & Pharmacology Source Type: research

Use of Inhaled Tobramycin in Cystic Fibrosis
Abstract Chronic infection with Pseudomonas aeruginosa is associated with poor outcomes in patients with cystic fibrosis (CF). It leads to a reduced quality of life, acceleration of the decline in lung function, and increased frequency and severity of pulmonary exacerbations. Tobramycin, administered by inhalation as a long-term therapy, decreases bacterial density in airways, reduces exacerbation frequency, and improves quality of life and lung function in patients with chronic P. aeruginosa infection. In the last decade, tobramycin inhalation has become an important contributor to CF treatment as a means to con...
Source: Advances in Therapy - January 1, 2015 Category: Drugs & Pharmacology Source Type: research

Etifoxine Versus Alprazolam for the Treatment of Adjustment Disorder with Anxiety: a Randomized Controlled Trial
Conclusion This randomized controlled trial provides support for the efficacy and safety of etifoxine in the management of adjustment disorder with anxiety, particularly when treatment discontinuation data are also assessed. Etifoxine has the important clinical advantage of having anxiolytic effects, which are not being associated with dependence. Pharmacotherapy was equally efficacious in patients with more severe anxiety symptoms at baseline. Additional work using longer-term follow-up and collecting data on cost-efficiency of management options would further advance the field of ADWA. ...
Source: Advances in Therapy - January 1, 2015 Category: Drugs & Pharmacology Source Type: research

A 6-Month Study Comparing Efficacy, Safety, and Tolerability of the Preservative-free Fixed Combination of Tafluprost 0.0015% and Timolol 0.5% versus Each of Its Individual Preservative-Free Components
Abstract Introduction The efficacy, safety and tolerability of the preservative-free (PF) fixed combination (FC) of tafluprost 0.0015% and timolol 0.5% (once daily) were compared to those of the individual components (PF tafluprost 0.0015% once daily and PF timolol 0.5% twice daily) in patients with open-angle glaucoma or ocular hypertension inadequately controlled on prior timolol or prostaglandin monotherapy for 6 months. Methods A stratified, double-masked, randomized, multicenter phase III study was conducted. A total of 189 prior timolol...
Source: Advances in Therapy - December 1, 2014 Category: Drugs & Pharmacology Source Type: research

Positive Effects of Soy Lecithin-Derived Phosphatidylserine plus Phosphatidic Acid on Memory, Cognition, Daily Functioning, and Mood in Elderly Patients with Alzheimer’s Disease and Dementia
Conclusion PS is efficiently absorbed after oral consumption. A positive influence of PS+PA on memory, mood, and cognition was demonstrated among elderly test subjects. Short-term supplementation with PS+PA in patients with AD showed a stabilizing effect on daily functioning, emotional state and self-reported general condition. The data encourage long-term studies with PS+PA in AD patients and other elderly with memory or cognition problems. (Source: Advances in Therapy)
Source: Advances in Therapy - December 1, 2014 Category: Drugs & Pharmacology Source Type: research

Management of Bone Disease in Gaucher Disease Type 1: Clinical Practice
Abstract Gaucher disease is a rare autosomal recessive disorder of glycosphingolipid metabolism resulting from deficient activity of the lysosomal enzyme beta-glucocerebrosidase that causes accumulation of glucosylceramide in tissue macrophage with damage to hematological, visceral, and skeletal organ systems. Severity and progression may vary independently among these domains, necessitating individualized therapy. Skeletal involvement is highly prevalent and often associated with intense pain, impaired mobility, and reduced quality of life. Enzyme replacement therapy improves parameters in all affected domains, ...
Source: Advances in Therapy - December 1, 2014 Category: Drugs & Pharmacology Source Type: research

Retrospective Analysis of Long-Term Adherence to and Persistence with DPP-4 Inhibitors in US Adults with Type 2 Diabetes Mellitus
Abstract Introduction Patients with type 2 diabetes mellitus (T2DM) must remain adherent and persistent on antidiabetic medications to optimize clinical benefits. This analysis compared adherence and persistence among adults initiating dipeptidyl peptidase-4 inhibitors (DPP-4is), sulfonylureas (SUs), and thiazolidinediones (TZDs) and between patients initiating saxagliptin or sitagliptin, two DPP-4is. Methods This retrospective cohort study utilized the US MarketScan® (Truven Health Analytics, Ann Arbor, MI, USA) Commercial and Medicare Supple...
Source: Advances in Therapy - December 1, 2014 Category: Drugs & Pharmacology Source Type: research

Safety Profile of Desmopressin Tablet for Enuresis in a Prospective Study
Conclusion Desmopressin tablet treatment is well tolerated in children with primary nocturnal enuresis, regardless of patient gender or age. Funding The desmopressin response in primary nocturnal enuresis study (DRIP- study) was funded by Ferring. (Source: Advances in Therapy)
Source: Advances in Therapy - December 1, 2014 Category: Drugs & Pharmacology Source Type: research

The Economic Impact of Improving Phosphate Binder Therapy Adherence and Attainment of Guideline Phosphorus Goals in Hemodialysis Patients: a Medicare Cost-Offset Model
Conclusion Increasing phosphate binder adherence and improving phosphorus control were associated with increased cost savings in total Medicare costs and inpatient costs. (Source: Advances in Therapy)
Source: Advances in Therapy - December 1, 2014 Category: Drugs & Pharmacology Source Type: research

Randomized Trial of Brinzolamide/Brimonidine Versus Brinzolamide Plus Brimonidine for Open-Angle Glaucoma or Ocular Hypertension
Abstract Introduction Fixed-combination intraocular pressure (IOP)—lowering medications simplify treatment regimens for patients requiring 2 ocular hypotensive agents to maintain sufficiently low IOP. The aim of this study was to evaluate the safety and efficacy of fixed-combination brinzolamide 1%/brimonidine 0.2% (BBFC) versus concomitant administration of brinzolamide 1% plus brimonidine 0.2% (BRINZ + BRIM) in patients with open-angle glaucoma or ocular hypertension. Methods This was a prospective, phase 3, multicenter, double-m...
Source: Advances in Therapy - December 1, 2014 Category: Drugs & Pharmacology Source Type: research

Patient Preferences for Change in Symptoms Associated with Opioid-Induced Constipation
Conclusions These results highlight the notable range of OIC symptoms most desired by patients to improve and demonstrate that bowel movements of only one more per week were important to register a meaningful improvement. The latter is particularly helpful for those assessing the minimal clinically important difference in treating this condition. (Source: Advances in Therapy)
Source: Advances in Therapy - December 1, 2014 Category: Drugs & Pharmacology Source Type: research

Erratum to: Comparison of Microlife BP A200 Plus and Omron M6 Blood Pressure Monitors to Detect Atrial Fibrillation in Hypertensive Patients
(Source: Advances in Therapy)
Source: Advances in Therapy - December 1, 2014 Category: Drugs & Pharmacology Source Type: research

Retrospective Study of Adherence to Glucagon-like Peptide-1 Receptor Agonist Therapy in Patients with Type 2 Diabetes Mellitus in the United States
Abstract Introduction Greater adherence to medications has been broadly demonstrated to be associated with improved clinical outcomes. However, there is limited real-world evidence on adherence to glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy in patients with type 2 diabetes mellitus (T2DM). Methods This retrospective cohort study used United States administrative claims data to compare adherence to GLP-1RAs in T2DM patients initiating exenatide once weekly (QW), exenatide twice daily (BID), or once-daily liraglutide (initiated therap...
Source: Advances in Therapy - November 1, 2014 Category: Drugs & Pharmacology Source Type: research